QurCan Therapeutics Inc.
Mohammad Ali Amini started their work experience in 2018 as the President & CEO of QurCan Therapeutics Inc. Mohammad Ali then held the position of CEO & Co-Founder at the same company from May 2018 to August 2022. In 2019, they also worked as an Entrepreneurship Post-Doc fellow at the University of Toronto & Ontario Brain Institute from April 2019 to present (no end date provided).
Mohammad Ali Amini completed their Doctor of Philosophy (PhD) degree in Pharmaceutics (Oncology) from the University of Toronto. Mohammad Ali pursued this educational accomplishment from 2013 to 2019.
This person is not in any teams
This person is not in any offices
QurCan Therapeutics Inc.
Nanology Labs has designed and is developing Manganescan®, a novel theranostic agent (MRI contrast agent/Radio-sensitizer) that allows detection of brain tumors at early stages using MRI. Simultaneously, it sensitizes cancer cells which improves radiation therapy outcomes. The agent is 3x more sensitive than current Gadolinium contrast agents(GBCAs), can cross the blood brain barrier and enables early and precise detection and targeting of brain cancer.